Figure 1. CAR-T Therapy
Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T) is an immunotherapy for chimeric antigen receptor T cells. The principle is that human T cells are modified by genetic engineering to express chimeric antigen receptor (CAR), that is, antibodies that recognize tumor cell surface antigens are connected with signal molecules needed to activate T cells, so as to enhance the specific killing of T cells to tumors. When CAR-T is infused back to the patient to bind to the target antigen on the surface of tumor cells, it activates the proliferation of CAR-T cells and the ability to kill tumor cells. CAR-T cells need to complete preclinical research before clinical trials. Creative Proteomics can provide CAR-T cell preparation services, preclinical in vitro cell experiments, preclinical in vivo verification experiments and other services.
Experimental process
A. Design of scFv and CAR frame
B. Packaging purification of CAR lentivirus
C. T cell infection and value-added clustering detection
D. Target cell killing test in vitro
E. In vivo killing experiment of model animals
CAR-T preclinical service flow
Our advantage
Mature and reliable tumor CAR-T cell experimental analysis platform: rich project experience, participate in major projects, publish high-level cooperation results.
The analysis contents and methods based on high-quality data analysis, pre-research and verification are indeed mature and feasible..
Creative Proteomics leads a rich team that uses the most rigorous experimental solutions and internationally recognized CAR-T cell experimental analysis techniques to obtain your customized information. Use the most accurate experimental results to help you better carry out tumor-related scientific research.
* For Research Use Only. Not for use in the treatment or diagnosis of disease.
Related Services:
